PROTALIX BIOTHERAPEUTICS, INC. (PLX)

[Spideyboy]

Great to hear this, and doesn't surprise me too much as my earlier review/post of the science behind the UC indication was that the theory checked out very nicely.

One thing I find interesting in the Yahoo article you posted was this line near the bottom.

Recently, the Company has successfully expressed a plant cell based anti TNF alfa protein comparable to adalimumab (Humira®) for oral administration.

I'm just curious why they mention this. I don't think it was necessary to mention this vis-a-vis the UC study, as it is obvious they are using anti-TNF as the active agent in OPRX for UC. And also interesting that they specify the comparison to Humira.

Would we be thinking that this is one their other newer pipeline products/indications that they are working on.

OPRX-106 efficacy in UC makes sense due to the plant cell wall only being about to be degraded in the colon, by the bacteria there, thus delivering the anti-TNF right at the necessary site. But not sure how they would be planning this for tackling an indication that Humira does, e.g. RA. Then the oral delivery system and release from the colon, would require much higher doses to get enough into the systemic blood system. And also one of the reasons for OPRX working in UC is that, in UC the colon cell walls are compromised allowing the relatively large anti-TNF molecule to get through the tighly packed intestinal cells and work on it's site of action which is on the "inside-body side" of the colon. In normal RA patients their colons probably work fine and thus not sure how we would get the anti-TNF through in the first place.

Anyone else have any thoughts on the quote and what it could mean, or am I thinking too much.